CYP2C9和VKORC1基因多态性与华人华法林用药量的关联

被引：11

作者：

彭齐

黄淑君

余亚军

周欣

机构：

[1] 武汉亚洲心脏病医院心外科

来源：

医药导报 | 2015年 / 34卷 / 06期

关键词：

华法林; 基因多态性; CYP2C9; VKORC1; 剂量预测模型;

D O I：

暂无

中图分类号：

R969 [临床药理学];

学科分类号：

摘要：

华法林是一种临床上广泛使用的香豆素类抗凝药。其治疗窗窄,用药剂量个体差异大,且容易发生溶血或血栓塞。华人所需要的华法林剂量远低于高加索人,这其中的差异与CYP2C9和VKORC1两个基因的多态性相关。其中,VKORC1基因是影响华法林需求剂量种族差异和个体差异的主要因素。目前,国内外学者已构建了基于不同种族和人群的华法林剂量预测模型,这为华法林的临床个体化用药提供依据和保障。该文从CYP2C9和VKORC1基因多态性与华人华法林用药量关联,以及基于华裔人群构建的华法林剂量预测模型两方面综述最新研究进展,以期为华法林的个体化治疗提供参考和理论依据。

引用

页码：775 / 779

页数：5

共 19 条

[11] Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients
Ohno, Masako
Yamamoto, Akiko
Ono, Ayumu
Miura, Genta
Funamoto, Masanobu
Takemoto, Yasuhiko
Otsu, Kinya
Kouno, Yasushi
Tanabe, Tomoko
Masunaga, Yuiko
Nonen, Shinpei
Fujio, Yasushi
Azuma, Junichi
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (11) : 1097 - 1103
[12] Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients[J] . Sheng-Wen Huang,Hai-Sheng Chen,Xian-Qun Wang,Ling Huang,Ding-Li Xu,Xiao-Jia Hu,Zhi-Hui Huang,Yong He,Kai-Ming Chen,Dao-Kang Xiang,Xiao-Ming Zou,Qiang Li,Li-Qin Ma,Hao-Fei Wang,Bao-Lin Chen,Liang Li,Yan-Kai Jia,Xiang-Min Xu.Pharmacogenetics and Genomics . 2009 (3)
[13] Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
Lindh, Jonatan D.
Holm, Lennart
Andersson, Marine L.
Rane, Anders
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (04) : 365 - 375
[14] Genetic factors contribute to patient-specific warfarin dose for Han Chinese[J] . Ting-Liang Wang,Hong-Lei Li,Wen-Ye Tjong,Qian-Su Chen,Guan-Sheng Wu,Hai-Tao Zhu,Zi-Shan Hou,Shu Xu,Sheng-Jun Ma,Madeline Wu,Susan Tai.Clinica Chimica Acta . 2008 (1)
[15] Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
Anderson, Jeffrey L.
Horne, Benjamin D.
Stevens, Scott M.
Grove, Amanda S.
Barton, Stephanie
Nicholas, Zachery P.
Kahn, Samera F. S.
May, Heidi T.
Samuelson, Kent M.
Muhlestein, Joseph B.
Carlquist, John F.
[J]. CIRCULATION, 2007, 116 (22) : 2563 - 2570
[16] Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients[J] . Liyan Miao,Jian Yang,Chenrong Huang,Zhenya Shen.European Journal of Clinical Pharmacology . 2007 (12)
[17] Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 — Rationale and perspectives[J] . Tong Yin,Toshiyuki Miyata.Thrombosis Research . 2006 (1)
[18] CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese[J] . Herng-Der Chern,Tzuu-Huei Ueng,Yi-Ping Fu,Chun-Wen Cheng.Clinica Chimica Acta . 2005 (1)
[19] Vitamin K epoxide reductase: homology, active site and catalytic mechanism[J] . Leo Goodstadt,Chris P Ponting.Trends in Biochemical Sciences . 2004 (6)

← 1 2 →